{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:07:17Z","timestamp":1791216437619,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00398","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T05:40:37Z","timestamp":1585633237000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Role of ADAM10 as a CD30 Sheddase in Classical Hodgkin Lymphoma"],"prefix":"10.3389","volume":"11","author":[{"given":"Hinrich P.","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana F.","family":"Paes Leme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1189\/jlb.3MR0315-136R","article-title":"The role of T cells in the microenvironment of Hodgkin lymphoma","volume":"99","author":"Wein","year":"2016","journal-title":"J Leukoc Biol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.canlet.2015.10.007","article-title":"Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance","volume":"380","author":"Aldinucci","year":"2016","journal-title":"Cancer Lett"},{"key":"B3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.semcancer.2013.07.002","article-title":"The microenvironment in classical Hodgkin lymphoma: An actively shaped and essential tumor component","volume":"24","author":"Liu","year":"2013","journal-title":"Semin Cancer Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1046\/j.1365-2141.2002.03768.x","article-title":"Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma","volume":"119","author":"Molin","year":"2002","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/hon.2900110404","article-title":"Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis","volume":"11","author":"Enblad","year":"1993","journal-title":"Hematol Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1182\/blood.V66.4.848.848","article-title":"The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells","volume":"66","author":"Stein","year":"1985","journal-title":"Blood."},{"key":"B7","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.4049\/jimmunol.157.8.3635","article-title":"Reverse signaling via CD30 ligand","volume":"157","author":"Wiley","year":"1996","journal-title":"J Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1172\/JCI24274","article-title":"Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion","volume":"116","author":"Fischer","year":"2006","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1083\/jcb.201211138","article-title":"Extracellular vesicles: exosomes, microvesicles, and friends","volume":"200","author":"Raposo","year":"2013","journal-title":"J Cell Biol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1242\/dev.076398","article-title":"Ectodomain shedding and ADAMs in development","volume":"139","author":"Weber","year":"2012","journal-title":"Development."},{"key":"B11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nri2567","article-title":"Membrane vesicles as conveyors of immune responses","volume":"9","author":"Thery","year":"2009","journal-title":"Nat Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"34299","DOI":"10.3402\/jev.v5.34299","article-title":"The International Society for Extracellular Vesicles launches the first massive open online course on extracellular vesicles","volume":"5","author":"Lasser","year":"2016","journal-title":"J Extracell Vesicles."},{"key":"B13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/path.4306","article-title":"Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma","volume":"232","author":"Hansen","year":"2014","journal-title":"J Pathol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"30523","DOI":"10.18632\/oncotarget.8864","article-title":"CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro","volume":"7","author":"Hansen","year":"2016","journal-title":"Oncotarget"},{"key":"B15","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/jmcb\/mjz008","article-title":"ADAM10 sheddase activation is controlled by cell membrane asymmetry","volume":"11","author":"Bleibaum","year":"2019","journal-title":"J Mol Cell Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1158\/0008-5472.CAN-06-2470","article-title":"ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro","volume":"67","author":"Eichenauer","year":"2007","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/leu.2009.230","article-title":"TNF-alpha-converting enzyme (TACE\/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species","volume":"24","author":"Vahdat","year":"2010","journal-title":"Leukemia."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3390\/cancers11111687","article-title":"Fibroblasts in nodular sclerosing classical hodgkin lymphoma are defined by a specific phenotype and protect tumor cells from brentuximab-vedotin induced injury","volume":"11","author":"Bankov","year":"2019","journal-title":"Cancers"},{"key":"B19","doi-asserted-by":"publisher","first-page":"14697","DOI":"10.1038\/s41598-018-32910-4","article-title":"Increased TIMP-3 expression alters the cellular secretome through dual inhibition of the metalloprotease ADAM10 and ligand-binding of the LRP-1 receptor","volume":"8","author":"Scilabra","year":"2018","journal-title":"Sci Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1042\/BJ20051013","article-title":"A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44","volume":"393","author":"Stoeck","year":"2006","journal-title":"Biochem J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1421889","DOI":"10.1080\/2162402X.2017.1421889","article-title":"Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells","volume":"7","author":"Tosetti","year":"2018","journal-title":"Oncoimmunology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12885-019-5415-9","article-title":"Challenges of driving CD30-directed CAR-T cells to the clinic","volume":"19","author":"Grover","year":"2019","journal-title":"BMC Cancer"},{"key":"B25","first-page":"1116","article-title":"An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30","volume":"58","author":"Hombach","year":"1998","journal-title":"Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood-2006-11-059139","article-title":"Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease","volume":"110","author":"Savoldo","year":"2007","journal-title":"Blood."},{"key":"B27","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/ijc.20278","article-title":"Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivo","volume":"111","author":"Matthey","year":"2004","journal-title":"Int J Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/sj.bjc.6601594","article-title":"A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours","volume":"90","author":"Wall","year":"2004","journal-title":"Br J Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1242\/jcs.112631","article-title":"Antibodies binding the ADAM10 substrate recognition domain inhibit Eph function","volume":"125","author":"Atapattu","year":"2012","journal-title":"J Cell Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41598-016-0013-4","article-title":"Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate","volume":"6","author":"Madoux","year":"2016","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.bbamcr.2017.06.005","article-title":"The metalloproteinase ADAM10: a useful therapeutic target?","volume":"1864","author":"Wetzel","year":"2017","journal-title":"Biochim Biophys Acta Mol Cell Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/ijc.2910600419","article-title":"Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4)","volume":"60","author":"Horn-Lohrens","year":"1995","journal-title":"Int J Cancer."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00398\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T09:15:39Z","timestamp":1695978939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00398\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2020.00398"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00398","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,31]]},"article-number":"398"}}